How Food and Ethnicity Affect a New Cancer Drug
Treatments studied
This early-stage study tests how a new experimental cancer drug (JPI-547) is processed by the body, and whether food and ethnic background change how it works. Researchers will give healthy men the drug and measure its safety and how their bodies handle it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy male between 19 and 50 years old
- Your weight is between 110–198 lbs (50–90 kg) and your BMI is between 18.5–29.9
- You have no major medical or surgical history, and no stomach/digestive problems
- You are Korean, Caucasian, or Chinese ethnicity
- You can stop smoking, alcohol, caffeine, and grapefruit for the study period
- You have not taken part in another clinical trial in the last few weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how eating food changes how your body absorbs a new experimental drug called VV913. Researchers will give you the drug with and without food to see if meals make a difference in how well it works.
This study tests a new drug for people with advanced stomach cancer that has not responded to at least two prior treatments. The goal is to see if it is safe and tolerable, and whether it can slow the cancer's growth.
This study tests whether adding JPI-547 to standard chemotherapy (modified FOLFIRINOX or gemcitabine with nab-paclitaxel) is safe and tolerable in people with advanced pancreatic cancer. If it works, it may improve treatment options for cancers that have spread or cannot be removed with surgery.
This trial tests a new combination of two drugs (JPI-547 and bevacizumab) as maintenance therapy after platinum-based chemotherapy and a PARP inhibitor. It's for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA mutation or HRD deficiency.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This research study examines circulating tumor cells (cancer cells in the bloodstream) to better understand which patients might benefit from PARP inhibitor drugs. You'll have blood samples collected to help doctors personalize cancer treatment decisions.
Hear when a new Healthy Volunteers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.